Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4155/bio.09.183 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Experts' perspectives on human gene editing in Switzerland.
J Community Genet
December 2024
Health Ethics and Policy Lab, Health Sciences and Technologies Department ETH Zurich, Zurich, Switzerland.
Despite many specialized studies on the views of the public or stakeholders who face inherited conditions that may be treatable by HGE, limited studies have focused on experts' views towards Human Gene Editing (HGE). Therefore, in this study we conducted exploratory interviews with 14 experts (scientists, clinicians, social scientists, lawyers) in Switzerland to assess their views towards HGE and how they expect the Swiss public to view HGE. We found general acceptance of Somatic Gene Editing (SGE), but opinions towards Germline Gene Editing (GGE) were more divided.
View Article and Find Full Text PDFPractices of Trans-National Corporations: The Need to Change Global Economic and Political Norms Comment on "National Public Health Surveillance of Corporations in Key Unhealthy Commodity Industries - A Scoping Review and Framework Synthesis".
Int J Health Policy Manag
December 2024
Stretton Health Equity, Stretton Institute, University of Adelaide, Adelaide SA, Australia.
Trans-national corporations (TNCs) are recognised as having an adverse impact on public health through the marketing and sale of unhealthy products. In addition to this some of their practices affect health, including taxation avoidance, lobbying politicians to gain favourable legislative and regulatory environments for their operations, and failure to abide by occupational health and safety standards. We argue that while considering the individual practices of commercial actors is crucial the true public health harms are only evident when the synergistic impacts of the practices are considered.
View Article and Find Full Text PDFIndirect Treatment Comparisons in Healthcare Decision Making: A Targeted Review of Regulatory Approval, Reimbursement, and Pricing Recommendations Globally for Oncology Drugs in 2021-2023.
Adv Ther
November 2024
EVERSANA™, Burlington, ON, Canada.
Introduction: Indirect treatment comparisons (ITCs) evaluate novel treatments compared to appropriate comparators when direct evidence is unavailable or infeasible. The objective of this study was to highlight the prevalence of different ITC methods in oncology drug submissions and to provide insights into how ITCs have been used in recent regulatory approval, reimbursement recommendations, or pricing decisions across various regions and diverse assessment frameworks.
Methods: A targeted literature review was conducted to identify assessment documents for oncology drug submissions that included ITCs.
Advancing patient-centric care: integrating patient reported outcomes for tolerability assessment in early phase clinical trials - insights from an expert virtual roundtable.
EClinicalMedicine
October 2024
Department of Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Article Synopsis
- Early phase clinical trials focus on evaluating the safety and tolerability of new therapies, primarily using investigator and lab results rather than patient feedback.
- A recent expert roundtable brought together 22 stakeholders to discuss the need for a universal patient-reported outcomes (PRO) model in early phase trials and how to effectively incorporate PROs to assess tolerability and guide treatment decisions.
- The discussions yielded key recommendations and identified priority areas for further research on integrating patient feedback into early trials to improve safety and symptom management.
The Role of Quality Assurance in Clinical Trials: Safeguarding Data Integrity and Compliance.
Cureus
August 2024
Department of Pharmaceutics, Sri Ramasamy Memorial (SRM) College of Pharmacy, SRM Institute of Science and Technology, Chengalpattu, IND.
Clinical trials, which investigate the effects of drugs in humans, aim to determine safety and efficacy while identifying adverse reactions. Data consistency and subject safety are crucial factors that determine the quality of clinical trials, necessitating overall quality management. There is a growing emphasis on implementing quality systems during the planning stages of clinical trials.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!